Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection|
|Study Start Date:||May 2007|
- Fludeoxyglucose (18 F)
- fluorodeoxyglucose (18 F)
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00373711
|Principal Investigator:||Andrei Iagaru||Stanford University|
|Principal Investigator:||Iain Ross McDougall||Stanford University|